Strategies to improve adherence and outcomes in patients with ulcerative colitis

Drugs

Volumn 68, Issue 18, 2008, Pages 2601-2609

  Kane, Sunanda V ^a  

^a MAYO CLINIC   (United States)

Author keywords

Patient compliance; Ulcerative colitis, treatment

Indexed keywords

MESALAZINE; SALAZOSULFAPYRIDINE;

AGE; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE ACTIVITY; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; FAMILY SIZE; HEALTH CARE COST; HEALTH EDUCATION; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; PATIENT COMPLIANCE; PATIENT EDUCATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SELF CARE; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; AMINOSALICYLIC ACIDS; COLITIS, ULCERATIVE; DRUG CARRIERS; HUMANS; MEDICATION ADHERENCE; PATIENT EDUCATION AS TOPIC; RISK FACTORS; TREATMENT OUTCOME;

EID: 57749184564     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/0003495-200868180-00006     Document Type: Review

References (48)

1. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85
2. Qureshi AI, Cohen RD. Mesalamine delivery systems: do they really make much difference? Adv Drug Deliv Rev 2005; 57: 281-302
3. Rogler G, Brand K, Vogl D, et al. Nuclear factor kappaB is activated in macrophages and epithelial cells of inflamed intestinal mucosa. Gastroenterology 1998; 115: 357-69
4. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53: V1-16
5. Miller NH. Compliance with treatment regimens in chronic asymptomatic diseases. Am J Med 1997; 102: 43-9
6. Riley SA, Mani V, Goodman MJ, et al. Why do patients with ulcerative colitis relapse? Gut 1990; 31: 179-83
7. van Hees PA, van Tongeren JH. Compliance to therapy in patients on a maintenance dose of sulfasalazine. J Clin Gastroenterol 1982; 4: 333-6
8. Stone MA, Mayberry JF, Baker R. Prevalence and management of inflammatory bowel disease: a cross-sectional study from central England. Eur J Gastroenterol Hepatol 2003; 15 (12): 1275-80
9. Kane SV, Cohen RD, Aikens JE, et al. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-33
10. Hall NJ, Rubin GP, Hungin AP, et al. Medicaiton beliefs among patients with inflammatory bowel disease who report low quality of life: a qualitative study [letter]. BMC Gastroenterol 2007; 7: 20
11. Moshkovska T, Stone M, Baker R, et al. Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis. Inflamm Bowel Dis 2008; 14 (6): 763-8
12. Kane SV. Systematic review: adherence issues in the treatment of ulcerative colitis. Aliment Pharmacol Ther 2006; 23: 577-85
13. Ediger JP, Walker JR, Graff L, et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 2007; 102: 1-10
14. Cerveny P, Bortlik M, Kobena A, et al. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm Bowel Dis 2007 Oct; 13 (10): 1244-9
15. Magowan S, Kane S, Lange J. 5-ASA prescription refill rates of ulcerative colitis are independent of formulation and dosing regimens [abstract]. Am J Gastroenterol 2006; 101: S447
16. Kane S, Magowan S, Accortt N, et al. Predictors of 5-ASA prescription persistence in patients with ulcerative colitis [abstract no. M1033]. Gastroenterology 2007; 132: A347
17. Kane S, Magowan S, Accortt N, et al. Predictors of 5-ASA prescription persistence during the chronic phase in patients with ulcerative colitis [abstract]. Am J Gastroenterol 2007; 102: A941
18. Kane SV, Aikens J, Huo D, et al. Medication adherence is associated with improved outcomes in patients with quiescent ulcerative colitis. Am J Med 2003; 113: 39-42
19. Kane S, Shaya F. Medication non-adherence is associated with increased medical health care costs. Dig Dis Sci 2008 Apr; 53 (4): 1020-4
20. Moody GA, Jayanthi V, Probert CS, et al. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol 1996; 8: 1179-83
21. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control Gastroenterology 1994; 107: 117-20
22. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145-53
23. Ullman T, Croog V, Itzkowitz S, et al. Preventing neoplastic progression in ulcerative colitis: role of mesalamine [abstract]. Gastroenterology 2003; 124 (4): S1662
24. Rubin DT, Losavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol 2006 Nov; 4 (11): 1346-50
25. Bernstein C, Metghe C, Blanachard JF. Does the use of 5-aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer [abstract]? Gastroenterology 2003; 124 (4): A280
26. Velayos F, Terdiman J, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005 Jun; 100 (6): 1345-53
27. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98: 1535-44
28. Davis TC, Wolf MS, Bass III PF, et al. Literacy and misunderstanding prescription drug labels. Ann Intern Med 2006; 145: 887-94
29. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med 2007; 167: 540-50
30. Dickinson RJ, King A, Wight DG, et al. Is continuous sulfasalazine necessary in the management of patients with ulcerative colitis? Results of a preliminary study. Dis Colon Rectum 1985; 28: 929-30
31. Bardazzi G, d'Albasio G, Bonamoni AG, et al. Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. Ital J Gastroenterol 1994; 26 (7): 334-7
32. Ardizzone S, Petrillo M, Imbesi V, et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission? Aliment Pharmacol Ther 1999; 13 (3): 373-9
33. Brunner M, Assandri R, Kletter K, et al. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Aliment Pharmacol Ther 2003; 17: 395-402
34. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of abremission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 2007; 5: 95-102
35. Sandborn WJ, Kamm M, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 2007 Jul 15; 26 (2): 205-15
36. Hanauer S, Sandborn W, Dellaire K, et al. Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: the ASCEND I trial. Can J Gastroenterol 2007 Dec; 21 (12): 827-34
37. Hanauer S, Sandborn W, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 2005; 100: 2478-85
38. Ferring Pharmaceuticals. Pentasa once daily in ulcerative colitis for maintenance of remission [ClinicalTrials.gov identifier NCT00209300]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Jun 9]
39. Kane S, Huo D, Magnanti K. A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 2003; 1: 170-3
40. Kane S, Holderman W, Jacques P, et al. Once daily versus conventional dosing of ph-dependent mesalamine long-term in the maintenance of quiescent ulcerative colitis: preliminary results from a randomized trial. Patient Preferences and Adherence 2008; 2: 253-8
41. Wong JM, Wei SC. Efficacy of Pentasa tablets for the treatment of inflammatory bowel disease. J Formos Med Assoc 2003; 102: 613-9
42. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. SPD476, a Aca, high-strength 5-ASA formulation induces remission of active, mild-to-moderate ulcerative colitis in subjects that are switched from low-dose oral 5-ASA therapy or are 5-ASA naive: an analysis of pooled data from two phase III studies [abstract no. T1139]. Gastroenterology 2007; 130 (4 Suppl. 2): A-482
43. Drossman DA, Leserman K, Li Z, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 701-12
44. Martin A, Leone L, Fries W, et al. What do patients want to know about their inflammatory bowel disease. Ital J Gastroenterol 1992; 24 (8): 477-80
45. Levy R, Feld AD. Increasing patient adherence to gastroenterology treatment and prevention regimens. Am J Gastroenterol 1999; 94: 1733-42
46. Nobel LM. Doctor-patient communication and adherence to treatment. In: Myers LB, Midence K, editors. Adherence to treatment in medical conditions. New York: Harwood Academic Publishers, 1998: 51-82
47. Sewitch MJ, Abrahamowicz M, Barkun A, et al. Patient nonadherence to medication in inflammatory bowel disease. Am J Gastroenterol 2003; 98 (7): 1535-44
48. Robinson A, Thompson DG, Wilkin D, et al. Guided self-management and patient-directed follow-up of ulcerative colitis: a randomized trial. Lancet 2001; 358 (9268): 976-81